Tobias Rader1, Timo Stöver1, Thomas Lenarz2, Hannes Maier2, Thomas Zahnert3, Thomas Beleites3, Rudolf Hagen4, Robert Mlynski4, Wolf Dieter Baumgartner5. 1. Department of Otolaryngology, University Hospital Frankfurt, Frankfurt am Main. 2. Department of Otorhinolaryngology, Hannover Medical School. 3. University Hospital Carl Gustav Carus, Dresden. 4. Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University Clinic Würzburg, Würzburg, Germany. 5. Ear, Nose and Throat Department, University Clinic Vienna, Vienna, Austria.
Abstract
OBJECTIVE: To determine the therapeutic success and safety of an active transcutaneous bone conduction implant (tBCI) in adult patients with conductive or mixed hearing loss. STUDY DESIGN: Retrospective case review. SETTING: Five university hospitals in Frankfurt, Hannover, Dresden, Würzburg, and Vienna. PATIENTS: Data were analyzed from 61 patients (31 women, 30 men) with a mean age of 50 years (min. 26, max. 80). Forty patients had mixed, and 21 conductive hearing loss. Typical etiologies were history of otitis media (n = 20) and cholesteatoma (n = 17). INTERVENTIONS: Implantation of the active tBCI. MAIN OUTCOME MEASURES: Data were analyzed for the following time points: up to 6 months postoperatively ("short-term"), 6 to 37 months postoperatively ("long-term"), and the last available measurement per patient ("most recent"). Pure-tone audiometry (air and bone conduction, AC and BC) and sound field thresholds with warble tones (WT), word recognition scores with Freiburger monosyllables (WRS), as well as speech reception thresholds (SRT) using the Oldenburg sentence test (OLSA) in quiet (SRT) and in noise (signal-to-noise ratio, SNR) were collected. RESULTS: No significant changes in air- and bone-conduction thresholds were observed after implantation. A mean WRS improvement of 54% using the active tBCI was shown at the short-term assessment, i.e., a mean score of 79% compared with 25% in the unaided condition. Results remained stable, with a mean score of 75% at the long-term assessment. SRT in noise improved by 3.6 dB SNR in the implanted ear at the short-term assessment. Overall six adverse events and four serious adverse events were reported, resulting in a rate of 9.84 and 6.56%, respectively. CONCLUSION: The tBCI clearly improves speech intelligibility in patients with conductive or mixed hearing loss, showing stable results up to 1 year post-implantation.
OBJECTIVE: To determine the therapeutic success and safety of an active transcutaneous bone conduction implant (tBCI) in adult patients with conductive or mixed hearing loss. STUDY DESIGN: Retrospective case review. SETTING: Five university hospitals in Frankfurt, Hannover, Dresden, Würzburg, and Vienna. PATIENTS: Data were analyzed from 61 patients (31 women, 30 men) with a mean age of 50 years (min. 26, max. 80). Forty patients had mixed, and 21 conductive hearing loss. Typical etiologies were history of otitis media (n = 20) and cholesteatoma (n = 17). INTERVENTIONS: Implantation of the active tBCI. MAIN OUTCOME MEASURES: Data were analyzed for the following time points: up to 6 months postoperatively ("short-term"), 6 to 37 months postoperatively ("long-term"), and the last available measurement per patient ("most recent"). Pure-tone audiometry (air and bone conduction, AC and BC) and sound field thresholds with warble tones (WT), word recognition scores with Freiburger monosyllables (WRS), as well as speech reception thresholds (SRT) using the Oldenburg sentence test (OLSA) in quiet (SRT) and in noise (signal-to-noise ratio, SNR) were collected. RESULTS: No significant changes in air- and bone-conduction thresholds were observed after implantation. A mean WRS improvement of 54% using the active tBCI was shown at the short-term assessment, i.e., a mean score of 79% compared with 25% in the unaided condition. Results remained stable, with a mean score of 75% at the long-term assessment. SRT in noise improved by 3.6 dB SNR in the implanted ear at the short-term assessment. Overall six adverse events and four serious adverse events were reported, resulting in a rate of 9.84 and 6.56%, respectively. CONCLUSION: The tBCI clearly improves speech intelligibility in patients with conductive or mixed hearing loss, showing stable results up to 1 year post-implantation.
Authors: Alexander M Huber; Bernd Strauchmann; Marco D Caversaccio; Wilhelm Wimmer; Thomas Linder; Nicola De Min; John-Martin Hempel; Marlene Pollotzek; Henning Frenzel; Frauke Hanke; Christof Röösli Journal: Otol Neurotol Date: 2022-02-01 Impact factor: 2.311
Authors: Katarzyna B Cywka; Piotr H Skarzynski; Bartlomiej Krol; Stavros Hatzopoulos; Henryk Skarzynski Journal: Eur Arch Otorhinolaryngol Date: 2022-02-19 Impact factor: 3.236